Cargando…

Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study

BACKGROUND: The raw costs of mitomycin C (MMC) and oxaliplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) differ substantially. We sought to compare the morbidity and toxicity profiles associated with the use of oxaliplatin and MMC in patients undergoing cytoreductive surgery (CRS) and HI...

Descripción completa

Detalles Bibliográficos
Autores principales: Benzaquen, Ella, Wang, Yifan, Wiseman, Stephanie, Rosenfeld, Velka, Sideris, Lucas, Dubé, Pierre, Pelletier, Jean-Sebastien, Vanounou, Tsafrir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Joule Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064255/
https://www.ncbi.nlm.nih.gov/pubmed/33651573
http://dx.doi.org/10.1503/cjs.001619
_version_ 1783682097602363392
author Benzaquen, Ella
Wang, Yifan
Wiseman, Stephanie
Rosenfeld, Velka
Sideris, Lucas
Dubé, Pierre
Pelletier, Jean-Sebastien
Vanounou, Tsafrir
author_facet Benzaquen, Ella
Wang, Yifan
Wiseman, Stephanie
Rosenfeld, Velka
Sideris, Lucas
Dubé, Pierre
Pelletier, Jean-Sebastien
Vanounou, Tsafrir
author_sort Benzaquen, Ella
collection PubMed
description BACKGROUND: The raw costs of mitomycin C (MMC) and oxaliplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) differ substantially. We sought to compare the morbidity and toxicity profiles associated with the use of oxaliplatin and MMC in patients undergoing cytoreductive surgery (CRS) and HIPEC for peritoneal carcinomatosis (PC) of colorectal or appendiceal origin, to evaluate whether the cost-effectiveness of these 2 agents should dictate drug choice. METHODS: We conducted a retrospective multi-institutional study of all patients with PC of colorectal or appendiceal origin treated with CRS-HIPEC using MMC or oxaliplatin from 2010 to 2015. Demographic, perioperative, morbidity, toxicity and cost data were compared between the 2 treatment groups and between cancer-origin subgroups. RESULTS: Forty-two patients treated with MMC and 76 treated with oxaliplatin were included in the study. Baseline demographic and tumour characteristics were comparable in the 2 groups, except that the patients treated with MMC had higher Charlson Comorbidity Index scores. The MMC group had a higher rate of cancer of colorectal origin (76.2% v. 57.9%, p = 0.047) and longer operative times (553 v. 320 min, p < 0.001). In the subgroup of patients whose cancer was of colorectal origin, patients treated with MMC had a higher transfusion rate (50.0% v. 28.6%, p = 0.023) and lower postoperative baseline hemoglobin level (100 v. 119 g/L, p = 0.002) than those treated with oxaliplatin. There was no difference in hematologic toxicity scores after controlling for postoperative anemia. There was no difference in the rates of major complications and 90-day mortality. However, MMC was less costly than oxaliplatin ($724 v. $8928). CONCLUSION: MMC and oxaliplatin are both suitable agents for HIPEC and are associated with comparable morbidity and toxicity profiles, regardless of cancer origin. Thus, we propose that cost-effectiveness should ultimately dictate drug selection.
format Online
Article
Text
id pubmed-8064255
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Joule Inc.
record_format MEDLINE/PubMed
spelling pubmed-80642552021-04-30 Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study Benzaquen, Ella Wang, Yifan Wiseman, Stephanie Rosenfeld, Velka Sideris, Lucas Dubé, Pierre Pelletier, Jean-Sebastien Vanounou, Tsafrir Can J Surg Research BACKGROUND: The raw costs of mitomycin C (MMC) and oxaliplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) differ substantially. We sought to compare the morbidity and toxicity profiles associated with the use of oxaliplatin and MMC in patients undergoing cytoreductive surgery (CRS) and HIPEC for peritoneal carcinomatosis (PC) of colorectal or appendiceal origin, to evaluate whether the cost-effectiveness of these 2 agents should dictate drug choice. METHODS: We conducted a retrospective multi-institutional study of all patients with PC of colorectal or appendiceal origin treated with CRS-HIPEC using MMC or oxaliplatin from 2010 to 2015. Demographic, perioperative, morbidity, toxicity and cost data were compared between the 2 treatment groups and between cancer-origin subgroups. RESULTS: Forty-two patients treated with MMC and 76 treated with oxaliplatin were included in the study. Baseline demographic and tumour characteristics were comparable in the 2 groups, except that the patients treated with MMC had higher Charlson Comorbidity Index scores. The MMC group had a higher rate of cancer of colorectal origin (76.2% v. 57.9%, p = 0.047) and longer operative times (553 v. 320 min, p < 0.001). In the subgroup of patients whose cancer was of colorectal origin, patients treated with MMC had a higher transfusion rate (50.0% v. 28.6%, p = 0.023) and lower postoperative baseline hemoglobin level (100 v. 119 g/L, p = 0.002) than those treated with oxaliplatin. There was no difference in hematologic toxicity scores after controlling for postoperative anemia. There was no difference in the rates of major complications and 90-day mortality. However, MMC was less costly than oxaliplatin ($724 v. $8928). CONCLUSION: MMC and oxaliplatin are both suitable agents for HIPEC and are associated with comparable morbidity and toxicity profiles, regardless of cancer origin. Thus, we propose that cost-effectiveness should ultimately dictate drug selection. Joule Inc. 2021-04 /pmc/articles/PMC8064255/ /pubmed/33651573 http://dx.doi.org/10.1503/cjs.001619 Text en © 2021 Joule Inc. or its licensors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Research
Benzaquen, Ella
Wang, Yifan
Wiseman, Stephanie
Rosenfeld, Velka
Sideris, Lucas
Dubé, Pierre
Pelletier, Jean-Sebastien
Vanounou, Tsafrir
Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study
title Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study
title_full Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study
title_fullStr Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study
title_full_unstemmed Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study
title_short Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study
title_sort morbidity associated with the use of oxaliplatin versus mitomycin c in hyperthermic intraperitoneal chemotherapy (hipec) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064255/
https://www.ncbi.nlm.nih.gov/pubmed/33651573
http://dx.doi.org/10.1503/cjs.001619
work_keys_str_mv AT benzaquenella morbidityassociatedwiththeuseofoxaliplatinversusmitomycincinhyperthermicintraperitonealchemotherapyhipecforperitonealcarcinomatosisofcolorectalorappendicealoriginamultiinstitutionalcomparativestudy
AT wangyifan morbidityassociatedwiththeuseofoxaliplatinversusmitomycincinhyperthermicintraperitonealchemotherapyhipecforperitonealcarcinomatosisofcolorectalorappendicealoriginamultiinstitutionalcomparativestudy
AT wisemanstephanie morbidityassociatedwiththeuseofoxaliplatinversusmitomycincinhyperthermicintraperitonealchemotherapyhipecforperitonealcarcinomatosisofcolorectalorappendicealoriginamultiinstitutionalcomparativestudy
AT rosenfeldvelka morbidityassociatedwiththeuseofoxaliplatinversusmitomycincinhyperthermicintraperitonealchemotherapyhipecforperitonealcarcinomatosisofcolorectalorappendicealoriginamultiinstitutionalcomparativestudy
AT siderislucas morbidityassociatedwiththeuseofoxaliplatinversusmitomycincinhyperthermicintraperitonealchemotherapyhipecforperitonealcarcinomatosisofcolorectalorappendicealoriginamultiinstitutionalcomparativestudy
AT dubepierre morbidityassociatedwiththeuseofoxaliplatinversusmitomycincinhyperthermicintraperitonealchemotherapyhipecforperitonealcarcinomatosisofcolorectalorappendicealoriginamultiinstitutionalcomparativestudy
AT pelletierjeansebastien morbidityassociatedwiththeuseofoxaliplatinversusmitomycincinhyperthermicintraperitonealchemotherapyhipecforperitonealcarcinomatosisofcolorectalorappendicealoriginamultiinstitutionalcomparativestudy
AT vanounoutsafrir morbidityassociatedwiththeuseofoxaliplatinversusmitomycincinhyperthermicintraperitonealchemotherapyhipecforperitonealcarcinomatosisofcolorectalorappendicealoriginamultiinstitutionalcomparativestudy